Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
Type 2-diabetes
Interventions
DRUG

Linagliptin

orally 5 mg/d for 4 weeks

DRUG

Placebo

orally once a day for 4 weeks

Trial Locations (2)

90471

Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Nuremberg

91054

Clinical Research Unit, Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen

All Listed Sponsors
lead

University of Erlangen-Nürnberg Medical School

OTHER

NCT01835678 - Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes. | Biotech Hunter | Biotech Hunter